GlobeNewswire Inc | Oct 7, 2021 08:05AM EDT

October 07, 2021

ISELIN, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical companyworking to develop and launch the first FDA-approved ophthalmic formulation of bevacizumabfor use in retinalindications, today announced that Suber S. Huang, MD, MBA, FASRS, Co-Founder and CEO of the Retina Center of Ohio, will present data from Outlook Therapeutics NORSE THREE supplemental safety study for ONS-5010 / LYTENAVA (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for use in retinal indications. Dr. Huangs oral presentation will take place at the 2021 Annual Meeting of the American Society of Retina Specialists being held in San Antonio, Texas.

Details for the presentation are as follows:

Safety Results of ONS-5010, an Ophthalmic Bevacizumab, in Treated Eyes of Patients with Wet AMD, DME and BRVOPresenter: Suber S. Huang, MD, MBA, FASRSDate and time: October 12, 2021, at 11:08-11:14 AM CDT

For more information and to register for this event, please visit https://www.asrs.org/annual-meeting.

About the American Society of Retina Specialists

The American Society of Retina Specialists is the largest organization of retina specialists in the world, representing over 3,000 physicians in all 50 US states, the District of Columbia, Puerto Rico, and 63 countries. The Society serves as a national advocate and primary source of clinical and scientific information and education for its members.

About Outlook Therapeutics, Inc.

Outlook Therapeutics is a biopharmaceutical company working to develop and launch ONS-5010/ LYTENAVA (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 ophthalmic bevacizumab is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to submit ONS-5010 ophthalmic bevacizumab to the U.S. FDA as a BLA under the PHSA 351(a) regulatory pathway. For more information, please visit www.outlooktherapeutics.com.

CONTACTS:Media Inquiries:Harriet UllmanVice PresidentLaVoie Health ScienceT: 617-669-3082hullman@lavoiehealthscience.com

Investor Inquiries:Jenene ThomasChief Executive OfficerJTC Team, LLCT: 833.475.8247OTLK@jtcir.com